NAUT · 10-Q · 2026Q1 · Full report

Regulatory / Compliance Costs

Nautilus Biotechnology, Inc. · 2026-04-28 · Importance 52 · Surprise 42

Nautilus expects selling, general and administrative expenses to increase substantially over the next several years as it hires personnel to support R&D and planned commercial growth and as it operates as a public company. Management specifically anticipates higher expenses related to accounting, audit, legal, regulatory compliance (including compliance with SEC rules and the Sarbanes-Oxley Act), insurance, investor/public relations and other administrative and professional services. These increased compliance and governance costs are presented as a structural driver of higher SG&A as the company scales its commercial and public-company infrastructure. The company states these expenses will be recorded in the periods incurred and could contribute materially to higher operating burn as commercialization ramps.